Structure-Based Drug Design
Drug design approach using three-dimensional molecular structures to guide binding, optimization, and selectivity.
Core metadata
- ID: structure_based_drug_design
- Era: Modern
- First known date: 1980 (decade)
- Region: Global structural biology and pharmaceutical research
- Review status: source_checked
- Maturity: established
Prerequisites
- DNA Structure (dna_structure)
- Pharmaceuticals & Drug Design (pharmaceuticals_drug_design)
- X-ray Crystallography (x_ray_crystallography)
Dependents
Fields
Field lanes
- Pharmaceuticals & Drug Development: Small-Molecule Drugs
Node sources
- Computational approaches streamlining drug discovery (Nature, 2023, review) • Supports: node, maturity
Prerequisite edge evidence
Edge/source evidence summary:
- Prerequisite edges: 3
- Average edge confidence: 68%
- Prerequisite sources: 3
- expert_inference: 3
| Prerequisite | Type | Confidence | Evidence level | Note | Sources |
|---|---|---|---|---|---|
| X-ray Crystallography (x_ray_crystallography) | enabling | 68% | expert_inference | X-ray Crystallography provides a capability that enables this technology without being the only possible path. |
|
| Pharmaceuticals & Drug Design (pharmaceuticals_drug_design) | enabling | 68% | expert_inference | Pharmaceuticals & Drug Design provides a capability that enables this technology without being the only possible path. |
|
| DNA Structure (dna_structure) | enabling | 68% | expert_inference | DNA Structure provides a capability that enables this technology without being the only possible path. |
|
This page is generated from canonical era JSON and is indexable by URL.